143 related articles for article (PubMed ID: 23343250)
1. Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis.
Ekwunife OI; Okafor CE; Ezenduka CC; Udeogaranya PO
Cost Eff Resour Alloc; 2013 Jan; 11(1):2. PubMed ID: 23343250
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
5. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country--the case of Tanzania.
Robberstad B; Hemed Y; Norheim OF
Cost Eff Resour Alloc; 2007 Feb; 5():3. PubMed ID: 17316431
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity.
Chowdhury EK; Ademi Z; Moss JR; Wing LMH; Reid CM;
Medicine (Baltimore); 2015 Mar; 94(9):e590. PubMed ID: 25738481
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage.
Ekwunife OI; Lhachimi SK
BMC Health Serv Res; 2017 Dec; 17(1):815. PubMed ID: 29216880
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.
Wailoo AJ; Sutton AJ; Cooper NJ; Turner DA; Abrams KR; Brennan A; Nicholson KG
Value Health; 2008; 11(2):160-71. PubMed ID: 18380629
[TBL] [Abstract][Full Text] [Related]
14. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
McCullagh L; Walsh C; Barry M
Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France.
Kaboré N; Marnat G; Rouanet F; Barreau X; Verpillot E; Menegon P; Maachi I; Berge J; Sibon I; Bénard A
Rev Neurol (Paris); 2019 Apr; 175(4):252-260. PubMed ID: 30642680
[TBL] [Abstract][Full Text] [Related]
16. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
17. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research.
Oostenbrink JB; Al MJ; Oppe M; Rutten-van Mölken MP
Value Health; 2008 Dec; 11(7):1070-80. PubMed ID: 19602213
[TBL] [Abstract][Full Text] [Related]
18. Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis.
Jutkowitz E; Alarid-Escudero F; Choi HK; Kuntz KM; Jalal H
Pharmacoeconomics; 2017 Oct; 35(10):1073-1085. PubMed ID: 28631197
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
